1. Home
  2. FXHO vs MNOV Comparison

FXHO vs MNOV Comparison

Compare FXHO & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FXHO

UTime Limited Class A Ordinary Shares

N/A

Current Price

$10.03

Market Cap

83.2M

Sector

N/A

ML Signal

N/A

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.38

Market Cap

67.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FXHO
MNOV
Founded
N/A
2000
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
67.9M
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
FXHO
MNOV
Price
$10.03
$1.38
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
136.4K
28.0K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$8.17
$1.17
52 Week High
$25.00
$1.96

Technical Indicators

Market Signals
Indicator
FXHO
MNOV
Relative Strength Index (RSI) 44.94 58.62
Support Level $9.20 $1.26
Resistance Level $15.32 $1.44
Average True Range (ATR) 2.30 0.04
MACD 0.30 0.00
Stochastic Oscillator 39.68 57.72

Price Performance

Historical Comparison
FXHO
MNOV

About FXHO UTime Limited Class A Ordinary Shares

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: